[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Protalix Biotherapeutics (PLX)

Protalix Biotherapeutics (PLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EDT

PBD : 21.00 (-1.08%)
PLX : 1.9100 (-3.54%)
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Company to host conference call and webcast at 8:00 a.m. EDT

PLX : 1.9100 (-3.54%)
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EDT

PLX : 1.9100 (-3.54%)
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

Company to host conference call and webcast at 8:00 a.m. EDT

PLX : 1.9100 (-3.54%)
Protalix BioTherapeutics Letter to Stockholders

CARMIEL, Israel , Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization...

PBD : 21.00 (-1.08%)
PLX : 1.9100 (-3.54%)
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator ® platform to jointly develop pharmaceutical candidates for rare renal indications...

PLX : 1.9100 (-3.54%)
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EST

PBD : 21.00 (-1.08%)
PLX : 1.9100 (-3.54%)
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

Company to host conference call and webcast at 8:00 a.m. EST

PLX : 1.9100 (-3.54%)
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (“Protalix” or “the...

PLX : 1.9100 (-3.54%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such investors...

PLX : 1.9100 (-3.54%)

Barchart Exclusives

A $3 Billion Reason to Buy Shell Stock Here (Plus It Has a Juicy 3.5% Dividend Yield)
Shell recently announced a $3 billion stock buyback program. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.